Physician profile
Deborah Keye
NPI 1164559159
$3,030.57
in general payments reported to CMS, 2019-2025
30 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $784 · 2023: $1,042 · 2024: $630 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.48 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.85 | 2021-2025 | |
| Lilly USA, LLC | $222.20 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $203.72 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $181.13 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $167.85 | 2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.71 | 2021-2023 | Synjardy, Jardiance |
| Novo Nordisk INC | $108.08 | 2021-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $88.14 | 2023-2025 | |
| Lucid Diagnostics INC. | $79.57 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $63.09 | 2023 | Nexletol, Contrave, Nexlizet |
| Biohaven Pharmaceuticals, INC. | $59.58 | 2021 | |
| Amarin Pharma, INC. | $53.38 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $52.65 | 2021-2023 | Breztri, Farxiga |
| Collegium Pharmaceutical, INC. | $50.58 | 2021-2023 | Belbuca, Xtampza |
| Glaxosmithkline, LLC. | $44.48 | 2021-2024 | Arexvy, Shingrix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.43 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $27.18 | 2022 | |
| Exact Sciences Corporation | $25.93 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $25.39 | 2024 | Auvelity |
| Abbott Laboratories | $21.05 | 2023 | Freestyle Libre 2 |
| Ultragenyx Pharmaceutical INC. | $19.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.45 | 2021 | |
| Eisai INC. | $18.31 | 2022 | |
| Cranial Technologies, INC | $17.95 | 2023 | Doc Band |
| Boston Scientific Corporation | $16.50 | 2024 | Wavewriter Alpha Prime 16 |
| Neurocrine Biosciences, INC. | $15.85 | 2025 | |
| Sanofi Pasteur INC. | $15.75 | 2022 | |
| Collaborative Care Diagnostics, LLC | $14.58 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.41 | 2022 | |
| Qorumpartners | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Keye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.